Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 2
2019 2
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination.
Frantzi M, Culig Z, Heidegger I, Mokou M, Latosinska A, Roesch MC, Merseburger AS, Makridakis M, Vlahou A, Blanca-Pedregosa A, Carrasco-Valiente J, Mischak H, Gomez-Gomez E. Frantzi M, et al. Among authors: blanca pedregosa a. Cancers (Basel). 2023 Feb 11;15(4):1166. doi: 10.3390/cancers15041166. Cancers (Basel). 2023. PMID: 36831508 Free PMC article.
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J. Frantzi M, et al. Among authors: blanca pedregosa a. Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16. Br J Cancer. 2019. PMID: 31092909 Free PMC article.
Telomere-based risk models for the early diagnosis of clinically significant prostate cancer.
Rubio Galisteo JM, Fernández L, Gómez Gómez E, de Pedro N, Cano Castiñeira R, Pedregosa AB, Guler I, Carrasco Valiente J, Esteban L, González S, Castelló N, Otero L, García J, Segovia E, Requena Tapia MJ, Najarro P. Rubio Galisteo JM, et al. Among authors: pedregosa ab. Prostate Cancer Prostatic Dis. 2021 Mar;24(1):88-95. doi: 10.1038/s41391-020-0232-4. Epub 2020 May 4. Prostate Cancer Prostatic Dis. 2021. PMID: 32367011 Free PMC article.
Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E, Carrasco-Valiente J, Campos-Hernández JP, Blanca-Pedregosa AM, Jiménez-Vacas JM, Ruiz-García J, Valero-Rosa J, Luque RM, Requena-Tapia MJ. Gómez-Gómez E, et al. Among authors: blanca pedregosa am. J Cell Mol Med. 2019 Feb;23(2):934-942. doi: 10.1111/jcmm.13994. Epub 2018 Nov 18. J Cell Mol Med. 2019. PMID: 30450757 Free PMC article.
Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.
Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Gómez-Gómez E, et al. Among authors: blanca pedregosa am. J Cell Mol Med. 2018 Nov;22(11):5688-5697. doi: 10.1111/jcmm.13845. Epub 2018 Sep 6. J Cell Mol Med. 2018. PMID: 30256519 Free PMC article.
European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.
Gómez-Gómez E, Carrasco-Valiente J, Blanca-Pedregosa A, Barco-Sánchez B, Fernandez-Rueda JL, Molina-Abril H, Valero-Rosa J, Font-Ugalde P, Requena-Tapia MJ. Gómez-Gómez E, et al. Among authors: blanca pedregosa a. Urology. 2017 Apr;102:85-91. doi: 10.1016/j.urology.2016.11.004. Epub 2016 Nov 10. Urology. 2017. PMID: 27840252